Jonathan Young - 14 Dec 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
14 Dec 2023
Net transactions value
-$11,273
Form type
4
Filing time
18 Dec 2023, 20:39:33 UTC
Previous filing
12 Dec 2023
Next filing
29 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale $11,273 -543 -0.29% $20.76 185,131 14 Dec 2023 Direct F1
holding AKRO Common Stock 20,000 14 Dec 2023 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 14 Dec 2023 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 14 Dec 2023 By JL Irrevocable Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
F2 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.